Literature DB >> 17716652

Reduction of CD4 positive T cells and improvement of pathological changes of collagen-induced arthritis by FTY720.

Fang Wang1, Wenfeng Tan, Dunming Guo, Shaoheng He.   

Abstract

FTY720 belongs to a new class of immunosuppressants. Little is known about its influence on T cell subtypes and pathological changes in arthritis. Here we illustrated the effect of FTY720 on peripheral T cell subsets and joint damage of collagen-induced arthritis rats. Rats were administered FTY720 or prednisone daily from day 0 to day 28. Body weight, hind paw swelling and arthritis index were measured. Bone destruction was determined by micro-computed tomography and histopathology, and T cell subsets were analyzed by flow cytometry and immunohistochemistry. The results showed that FTY720 inhibited the development of arthritis. Radiological analysis revealed that FTY720 treated collagen-induced arthritic rats had much less joint damage in comparison to untreated collagen-induced arthritic rats. Histological study showed that collagen-induced arthritic rats suffered from inflammatory cell infiltration and synovial hyperplasia in their joints, and FTY720 treatment clearly reduced these pathological changes. Immunohistochemical analysis showed that FTY720 treatment significantly decreased the number of CD4(+) T cells in the synovium of collagen-induced arthritic rats. Collagen-induced arthritic rats appeared to have more CD4(+), but not CD8(+) T cells in their peripheral blood than normal control rats. Following FTY720 treatment, peripheral blood CD3(+) and CD4(+) T cells in collagen-induced arthritic rats were significantly decreased. In conclusion, FTY720 is an effective compound in the treatment of collagen-induced arthritic rats and in reducing CD4(+) T cells in collagen-induced arthritic rats.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17716652     DOI: 10.1016/j.ejphar.2007.07.029

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

1.  An investigation of the impact of the location and timing of antigen-specific T cell division on airways inflammation.

Authors:  S Hutchison; B S W Choo-Kang; V B Gibson; R V Bundick; A J Leishman; J M Brewer; I B McInnes; P Garside
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

2.  Sphingosine kinase and sphingosine-1-phosphate: regulators in autoimmune and inflammatory disease.

Authors:  Ashley J Snider
Journal:  Int J Clin Rheumtol       Date:  2013-08-01

3.  Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo.

Authors:  Margarita Dominguez-Villar; Khadir Raddassi; Ann Caroline Danielsen; Joseph Guarnaccia; David A Hafler
Journal:  J Autoimmun       Date:  2018-08-16       Impact factor: 7.094

Review 4.  Sphingosine kinase: Role in regulation of bioactive sphingolipid mediators in inflammation.

Authors:  Ashley J Snider; K Alexa Orr Gandy; Lina M Obeid
Journal:  Biochimie       Date:  2010-02-13       Impact factor: 4.079

Review 5.  Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases.

Authors:  Nathalie Burg; Jane E Salmon; Timothy Hla
Journal:  Nat Rev Rheumatol       Date:  2022-05-04       Impact factor: 20.543

6.  Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints.

Authors:  Adrienn Angyal; Colt Egelston; Tamás Kobezda; Katalin Olasz; Anna László; Tibor T Glant; Katalin Mikecz
Journal:  Arthritis Res Ther       Date:  2010-03-18       Impact factor: 5.156

7.  Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.

Authors:  F L Scott; B Clemons; J Brooks; E Brahmachary; R Powell; H Dedman; H G Desale; G A Timony; E Martinborough; H Rosen; E Roberts; M F Boehm; R J Peach
Journal:  Br J Pharmacol       Date:  2016-04-28       Impact factor: 8.739

8.  Loss of neutral ceramidase increases inflammation in a mouse model of inflammatory bowel disease.

Authors:  Ashley J Snider; Bill X Wu; Russell W Jenkins; Jonathan A Sticca; Toshihiko Kawamori; Yusuf A Hannun; Lina M Obeid
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-08-31       Impact factor: 3.072

Review 9.  Inflammatory Cell Migration in Rheumatoid Arthritis: A Comprehensive Review.

Authors:  Erin Nevius; Ana Cordeiro Gomes; João P Pereira
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 10.817

10.  The immunosuppressant FTY720 (fingolimod) enhances glycosaminoglycan depletion in articular cartilage.

Authors:  Martin H Stradner; Hannes Angerer; Thomas Ortner; Florentine C Fuerst; Daniela Setznagl; Marie-Luise Kremser; Josef Hermann; Winfried B Graninger
Journal:  BMC Musculoskelet Disord       Date:  2011-12-12       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.